MedTrace Logo

A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients

NCT01007630 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2013-12-02

No results posted yet for this study

Summary

A decrease or loss of the sense of smell is very common in patients with Parkinson's Disease even in the earliest stages of the disease. There have been no treatments that have been proven to improve sense of smell in patients with Parkinson's Disease.

Rasagiline (brand name: Azilect) was approved by the U.S. Food and Drug Administration (FDA) on May 16th 2006 to be used by Parkinson's patients to treat the motor symptoms associated with the disease. The purpose of this study is to see if there is change in sense of smell after starting Rasagiline.

Conditions

Interventions

DRUG

Rasagiline

0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)

DRUG

Placebo

0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)

Sponsors & Collaborators

  • Teva Neuroscience, Inc.

    collaborator INDUSTRY

  • The Parkinson's Institute

    lead OTHER

Principal Investigators

  • Grace S Liang, MD · The Parkinson's Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01007630 on ClinicalTrials.gov